Pekin Hardy Strauss Inc. Sells 273 Shares of AbbVie Inc. $ABBV

Pekin Hardy Strauss Inc. lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 0.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,595 shares of the company’s stock after selling 273 shares during the period. Pekin Hardy Strauss Inc.’s holdings in AbbVie were worth $5,865,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ABBV. Conning Inc. increased its holdings in shares of AbbVie by 7.1% in the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after purchasing an additional 12,690 shares during the period. Dohj LLC grew its position in AbbVie by 41.8% during the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after buying an additional 1,335 shares in the last quarter. First Hawaiian Bank grew its position in AbbVie by 0.8% during the second quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock worth $1,403,000 after buying an additional 60 shares in the last quarter. Narus Financial Partners LLC increased its stake in AbbVie by 25.3% in the 1st quarter. Narus Financial Partners LLC now owns 1,988 shares of the company’s stock worth $417,000 after acquiring an additional 401 shares during the last quarter. Finally, BankPlus Trust Department raised its holdings in shares of AbbVie by 3.3% in the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company’s stock valued at $5,033,000 after acquiring an additional 855 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.25% of the stock is owned by insiders.

AbbVie Stock Performance

NYSE:ABBV opened at $219.13 on Friday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $244.81. The firm has a market cap of $387.11 billion, a PE ratio of 104.35, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The business has a 50 day moving average price of $223.06 and a 200-day moving average price of $201.96.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the firm earned $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is currently 524.24%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ABBV shares. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday. Wells Fargo & Company boosted their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Daiwa Capital Markets raised shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective for the company in a report on Thursday, August 7th. Finally, Citigroup cut their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $238.05.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.